Holen Sie sich die Stockscreener-App
2.83
1.05%
-0.03
Handel nachbörslich:
2.80
-0.03
-1.06%
Schlusskurs vom Vortag:
$2.86
Offen:
$2.9
24-Stunden-Volumen:
67,740
Relative Volume:
0.27
Marktkapitalisierung:
$94.46M
Einnahmen:
$210.00K
Nettoeinkommen (Verlust:
$-11.03M
KGV:
-8.4076
EPS:
-0.3366
Netto-Cashflow:
$-7.17M
1W Leistung:
-0.70%
1M Leistung:
+0.35%
6M Leistung:
-3.58%
1J Leistung:
+0.71%
1-Tages-Spanne:
$2.81
$2.9299
1-Wochen-Bereich:
$2.81
$3.05
52-Wochen-Spanne:
$2.331
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Firmenname
Anixa Biosciences Inc
Sektor
Branche
Telefon
408-708-9808
Adresse
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.83 | 95.47M | 210.00K | -11.03M | -7.17M | -0.3366 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-21 | Eingeleitet | Maxim Group | Buy |
| 2022-12-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-04-12 | Eingeleitet | H.C. Wainwright | Buy |
Anixa Biosciences Inc Aktie (ANIX) Neueste Nachrichten
Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress - Yahoo Finance
Can Anixa Biosciences Inc keep up with sector leadersTrade Risk Assessment & Verified Stock Trade Ideas - baoquankhu1.vn
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast - Barchart.com
Anixa Biosciences Shareholders Back Board and Compensation - TipRanks
Anixa Biosciences, Inc. (ANIX) Shareholder/Analyst CallSlideshow (NASDAQ:ANIX) 2026-03-11 - Seeking Alpha
Anixa Biosciences Inc. Q1 2026 Financial Report: Earnings, Balance Sheet, and Key Disclosures - Minichart
ANIXA BIOSCIENCES ($ANIX) Releases Q1 2026 Earnings - Quiver Quantitative
Anixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Anixa 10-Q: $0 Revenue, $(0.08) EPS for Q3 (Jan 31, 2026) - TradingView
Anixa Biosciences (NASDAQ: ANIX) narrows loss and advances cancer vaccine and CAR-T programs - Stock Titan
Anixa receives Korean patent allowance for breast cancer vaccine By Investing.com - Investing.com Australia
Anixa Biosciences (ANIX) Secures Patent in South Korea for Breas - GuruFocus
Anixa receives Korean patent allowance for breast cancer vaccine - Investing.com
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology - Morningstar
Anixa Biosciences (NASDAQ:ANIX) Upgraded to Hold at Wall Street Zen - MarketBeat
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ANIX SEC FilingsAnixa Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ANIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Anixa Biosciences (ANIX) to Release Earnings on Tuesday - MarketBeat
Anixa Biosciences to host 2026 annual meeting of stockholders and provide corporate update highlighting recent clinical and regulatory progress - marketscreener.com
Anixa Biosciences To Host 2026 Annual Meeting Of Stockholders And Provide Corporate Update Highlighting Recent Clinical And Regulatory Progress - TradingView
Anixa to outline ovarian CAR-T survival, breast cancer vaccine data - Stock Titan
Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat - Investing News Network
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote - GuruFocus
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic - Intellectia AI
Can Anixa Biosciences Inc. stock double in the next yearJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
ANIX: Robust 2025 Milestones Set the Stage for a Pivotal 2026 - Smartkarma
Anixa Biosciences to Present at the iAccess Alpha Virtual Best I - GuruFocus
Whale Trades: Will Anixa Biosciences Inc. stock reach all time highs in 2025 - mfd.ru
Breast cancer vaccine now in early clinical trials: What to know - abcnews.com
Will Anixa Biosciences Inc. stock reach all time highs in 20252025 Price Targets & Community Consensus Trade Alerts - mfd.ru
Why Anixa Biosciences Inc. stock is seen as undervalued2025 Fundamental Recap & Reliable Breakout Forecasts - mfd.ru
Anixa Biosciences Updates Ovarian Cancer CAR-T Trial Outcomes - Intellectia AI
Aug Momentum: Can Anixa Biosciences Inc maintain its current growth rate2025 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Anixa Biosciences Inc. keep up with sector leadersJuly 2025 Sentiment & Risk Managed Investment Entry Signals - mfd.ru
Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance - MarketBeat
ANIX: Pivotal data from advanced cancer trials and fiscal discipline set the stage for a transformative 2026 - TradingView
Anixa reports promising survival data in ovarian cancer CAR-T trial - Investing.com Australia
Anixa Biosciences Reports Encouraging Patient Survival Observati - GuruFocus
Why Anixa Biosciences Inc. stock is trending among retail tradersWeekly Trend Recap & Daily Profit Focused Screening - mfd.ru
Anixa Biosciences (ANIX) Reports Positive Data in Ovarian Cancer CAR-T Trial - GuruFocus
Anixa Advances Ovarian Cancer CAR-T With Higher Dosing - TipRanks
Anixa Biosciences reports encouraging patient survival observations in ovarian cancer CAR-T trial - marketscreener.com
Anixa Biosciences Reports Encouraging Patient Survival Observations In Ovarian Cancer Car-T Trial - TradingView
ANIX: Major dose escalation approved after strong survival and safety data in ovarian cancer CAR-T trial - TradingView
Anixa Biosciences Reports Encouraging Data in Ovarian Cancer CAR-T Trial - TradingView
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation - PR Newswire
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues - Sahm
Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation - Yahoo Finance
Anixa Biosciences (NASDAQ:ANIX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Finanzdaten der Anixa Biosciences Inc-Aktie (ANIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):